 |
|
| Pagina dedicata alle informazioni sui farmaci di competenza dell'EMA, relativa alle autorizzazioni e alle segnalazioni di farmacovigilanza | |
EMA: Documentazione sui farmaci
NUOVI FARMACI, SEGNALAZIONI EMA
-
Human medicines European public assessment report (EPAR): Winlevi, clascoterone, Status: Opinion under re-examination
Human medicines European public assessment report (EPAR): Winlevi, clascoterone, Status: Opinion under re-examination
Human medicines European public assessment report (EPAR): Winlevi, clascoterone, Status: Opinion under re-examination
Source: New medicines and opinions: human
Created on: May 15, 2025 | 10:43 am
New medicines and opinions: human | May 15, 2025 | 10:43 am -
Human medicines European public assessment report (EPAR): Dazublys, trastuzumab, Status: Opinion
Human medicines European public assessment report (EPAR): Dazublys, trastuzumab, Status: Opinion
Human medicines European public assessment report (EPAR): Dazublys, trastuzumab, Status: Opinion
Source: New medicines and opinions: human
Created on: Apr 28, 2025 | 09:55 am
New medicines and opinions: human | Apr 28, 2025 | 09:55 am -
Human medicines European public assessment report (EPAR): Ziihera, zanidatamab, Status: Opinion
Human medicines European public assessment report (EPAR): Ziihera, zanidatamab, Status: Opinion
Human medicines European public assessment report (EPAR): Ziihera, zanidatamab, Status: Opinion
Source: New medicines and opinions: human
Created on: Apr 25, 2025 | 16:05 pm
New medicines and opinions: human | Apr 25, 2025 | 16:05 pm -
Human medicines European public assessment report (EPAR): Denosumab BBL, denosumab, Status: Opinion
Human medicines European public assessment report (EPAR): Denosumab BBL, denosumab, Status: Opinion
Human medicines European public assessment report (EPAR): Denosumab BBL, denosumab, Status: Opinion
Source: New medicines and opinions: human
Created on: Apr 25, 2025 | 16:03 pm
New medicines and opinions: human | Apr 25, 2025 | 16:03 pm -
Human medicines European public assessment report (EPAR): Enwylma, denosumab, Status: Opinion
Human medicines European public assessment report (EPAR): Enwylma, denosumab, Status: Opinion
Human medicines European public assessment report (EPAR): Enwylma, denosumab, Status: Opinion
Source: New medicines and opinions: human
Created on: Apr 25, 2025 | 16:02 pm
New medicines and opinions: human | Apr 25, 2025 | 16:02 pm -
Human medicines European public assessment report (EPAR): Duvyzat, givinostat, Status: Opinion
Human medicines European public assessment report (EPAR): Duvyzat, givinostat, Status: Opinion
Human medicines European public assessment report (EPAR): Duvyzat, givinostat, Status: Opinion
Source: New medicines and opinions: human
Created on: Apr 25, 2025 | 16:02 pm
New medicines and opinions: human | Apr 25, 2025 | 16:02 pm -
Human medicines European public assessment report (EPAR): Vevzuo, denosumab, Status: Opinion
Human medicines European public assessment report (EPAR): Vevzuo, denosumab, Status: Opinion
Human medicines European public assessment report (EPAR): Vevzuo, denosumab, Status: Opinion
Source: New medicines and opinions: human
Created on: Apr 25, 2025 | 16:02 pm
New medicines and opinions: human | Apr 25, 2025 | 16:02 pm -
Human medicines European public assessment report (EPAR): Yaxwer, denosumab, Status: Opinion
Human medicines European public assessment report (EPAR): Yaxwer, denosumab, Status: Opinion
Human medicines European public assessment report (EPAR): Yaxwer, denosumab, Status: Opinion
Source: New medicines and opinions: human
Created on: Apr 25, 2025 | 16:00 pm
New medicines and opinions: human | Apr 25, 2025 | 16:00 pm -
Human medicines European public assessment report (EPAR): Zadenvi, denosumab, Status: Opinion
Human medicines European public assessment report (EPAR): Zadenvi, denosumab, Status: Opinion
Human medicines European public assessment report (EPAR): Zadenvi, denosumab, Status: Opinion
Source: New medicines and opinions: human
Created on: Apr 25, 2025 | 16:00 pm
New medicines and opinions: human | Apr 25, 2025 | 16:00 pm -
Human medicines European public assessment report (EPAR): Denbrayce, denosumab, Status: Opinion
Human medicines European public assessment report (EPAR): Denbrayce, denosumab, Status: Opinion
Human medicines European public assessment report (EPAR): Denbrayce, denosumab, Status: Opinion
Source: New medicines and opinions: human
Created on: Apr 25, 2025 | 16:00 pm
New medicines and opinions: human | Apr 25, 2025 | 16:00 pm -
Human medicines European public assessment report (EPAR): Alyftrek, deutivacaftor / tezacaftor / vanzacaftor, Status: Opinion
Human medicines European public assessment report (EPAR): Alyftrek, deutivacaftor / tezacaftor / vanzacaftor, Status: Opinion
Human medicines European public assessment report (EPAR): Alyftrek, deutivacaftor / tezacaftor / vanzacaftor, Status: Opinion
Source: New medicines and opinions: human
Created on: Apr 25, 2025 | 16:00 pm
New medicines and opinions: human | Apr 25, 2025 | 16:00 pm -
Human medicines European public assessment report (EPAR): Attrogy, diflunisal, Status: Opinion
Human medicines European public assessment report (EPAR): Attrogy, diflunisal, Status: Opinion
Human medicines European public assessment report (EPAR): Attrogy, diflunisal, Status: Opinion
Source: New medicines and opinions: human
Created on: Apr 25, 2025 | 16:00 pm
New medicines and opinions: human | Apr 25, 2025 | 16:00 pm -
Human medicines European public assessment report (EPAR): Oczyesa, octreotide, Status: Opinion
Human medicines European public assessment report (EPAR): Oczyesa, octreotide, Status: Opinion
Human medicines European public assessment report (EPAR): Oczyesa, octreotide, Status: Opinion
Source: New medicines and opinions: human
Created on: Apr 25, 2025 | 16:00 pm
New medicines and opinions: human | Apr 25, 2025 | 16:00 pm -
Human medicines European public assessment report (EPAR): Sephience, sepiapterin, Status: Opinion
Human medicines European public assessment report (EPAR): Sephience, sepiapterin, Status: Opinion
Human medicines European public assessment report (EPAR): Sephience, sepiapterin, Status: Opinion
Source: New medicines and opinions: human
Created on: Apr 25, 2025 | 16:00 pm
New medicines and opinions: human | Apr 25, 2025 | 16:00 pm -
Human medicines European public assessment report (EPAR): Tepezza, teprotumumab, Status: Opinion
Human medicines European public assessment report (EPAR): Tepezza, teprotumumab, Status: Opinion
Human medicines European public assessment report (EPAR): Tepezza, teprotumumab, Status: Opinion
Source: New medicines and opinions: human
Created on: Apr 25, 2025 | 16:00 pm
New medicines and opinions: human | Apr 25, 2025 | 16:00 pm -
Human medicines European public assessment report (EPAR): Izamby, denosumab, Status: Opinion
Human medicines European public assessment report (EPAR): Izamby, denosumab, Status: Opinion
Human medicines European public assessment report (EPAR): Izamby, denosumab, Status: Opinion
Source: New medicines and opinions: human
Created on: Apr 25, 2025 | 16:00 pm
New medicines and opinions: human | Apr 25, 2025 | 16:00 pm -
Human medicines European public assessment report (EPAR): Junod, denosumab, Status: Opinion
Human medicines European public assessment report (EPAR): Junod, denosumab, Status: Opinion
Human medicines European public assessment report (EPAR): Junod, denosumab, Status: Opinion
Source: New medicines and opinions: human
Created on: Apr 25, 2025 | 16:00 pm
New medicines and opinions: human | Apr 25, 2025 | 16:00 pm